At ISC 2026, a 20-minute IP-RPLC–UV assay distinguished mRNA capping variants without mass spectrometry, matching a UHPLC–MS reference method.
|Articles|July 1, 2006
- Special Issues-07-01-2006
- Volume 0
- Issue 0
The Growing Regulatory Burden and Revolution in Global Clinical Trials
At the same time the pharmaceutical industry faces new and complex issues with the drug development process and clinical trial environment, regulatory policies are increasing and adding to the burden of cost and time to market.
Advertisement
Articles in this issue
about 20 years ago
Analytical Instrument Qualificationabout 20 years ago
GMP and Phase I Clinical Trials: Streamlining the Critical Path?about 20 years ago
Team Effortabout 20 years ago
Rated PG: Pharmaceutical Guidance Suggestedabout 20 years ago
European Clinical Trial Regulations Undergo a Slow Revolutionabout 20 years ago
Moving Biotech Products from CBER to CDER: A Work in Progressabout 20 years ago
FDA Video Interview Conducted by Jill Wechsler, Washington Bureau Chiefabout 20 years ago
New Climateabout 20 years ago
2006: A Regulatory OdysseyAdvertisement
Related to this article
Advertisement
Advertisement